Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of ABO2102 in Participants With KRAS Mutant Solid Tumors

NCT07455617 is registered in ClinicalTrials.gov with Suzhou Abogen Biosciences Co., Ltd. as lead sponsor.

NCT NCT07455617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07455617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of ABO2102 in Participants With KRAS Mutant Solid Tumors
Lead sponsor
Suzhou Abogen Biosciences Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 24, 2026
Completion date
February 28, 2030
Enrollment
101 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced / metastatic solid tumor